Top ▲
Quaternary Structure: Complexes |
Interferon-α/β receptor |
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 557 | 21q22.11 | IFNAR1 | interferon alpha and beta receptor subunit 1 | |
Mouse | 1 | 590 | 16 52.98 cM | Ifnar1 | interferon (alpha and beta) receptor 1 | |
Rat | - | - | Ifnar1 | interferon alpha and beta receptor subunit 1 |
Previous and Unofficial Names |
IFRC | interferon (alpha and beta) receptor 1 | interferon (alpha, beta and omega) receptor 1 | Ifar | IFN-alpha/betaR |
Database Links | |
Alphafold | P17181 (Hs), P33896 (Mm) |
CATH/Gene3D | 2.60.40.10 |
ChEMBL Target | CHEMBL1887 (Hs) |
DrugBank Target | P17181 (Hs) |
Ensembl Gene | ENSG00000142166 (Hs), ENSMUSG00000022967 (Mm), ENSRNOG00000028594 (Rn) |
Entrez Gene | 3454 (Hs), 15975 (Mm), 288264 (Rn) |
Human Protein Atlas | ENSG00000142166 (Hs) |
KEGG Gene | hsa:3454 (Hs), mmu:15975 (Mm), rno:288264 (Rn) |
OMIM | 107450 (Hs) |
Pharos | P17181 (Hs) |
UniProtKB | P17181 (Hs), P33896 (Mm) |
Wikipedia | IFNAR1 (Hs) |
Natural/Endogenous Ligands |
IFN-β {Sp: Human} |
Download all structure-activity data for this target as a CSV file
Agonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
IFNAR1 is a subunit of the functional receptor for type I interferons (NOT interferon γ). Type I interferons (IFN) exhibit an established anti-viral action. However, type I IFN signalling also appears to play a role in impaired resistance to a range of other pathogens (e.g. bacterial infection) [2-3]. A rare mutation in IFNAR1, identified in the Chinese population, that impairs type I IFN signalling, is associated with increased resistance to tuberculosis infection and reduced TB symptoms [5]. |
Immuno Process Associations | ||
|
||
|
||
|
||
|
Biologically Significant Variants | ||||||||||||||
|
1. Cardarelli JM, Witte A, Srinivasan M. (2010) Interferon alpha receptor I antibodies and their use. Patent number: US7662381. Assignee: Medarex, Inc.. Priority date: 21/06/2004. Publication date: 16/02/2010.
2. Carrero JA. (2013) Confounding roles for type I interferons during bacterial and viral pathogenesis. Int Immunol, 25 (12): 663-9. [PMID:24158954]
3. Ng CT, Mendoza JL, Garcia KC, Oldstone MB. (2016) Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes. Cell, 164 (3): 349-52. [PMID:26824652]
4. Ward AC, Touw I, Yoshimura A. (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood, 95 (1): 19-29. [PMID:10607680]
5. Zhang G, deWeerd NA, Stifter SA, Liu L, Zhou B, Wang W, Zhou Y, Ying B, Hu X, Matthews AY et al.. (2018) A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans. Nat Commun, 9 (1): 85. [PMID:29311663]
Interferon receptor family: interferon α/β receptor 1. Last modified on 18/01/2018. Accessed on 02/11/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1723.